Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 76

2.

Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.

Greenspan SL, Nelson JB, Trump DL, Resnick NM.

Ann Intern Med. 2007 Mar 20;146(6):416-24.

PMID:
17371886
[PubMed - indexed for MEDLINE]
3.

Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.

Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1239-45. doi: 10.1016/j.ijrobp.2012.11.007. Epub 2012 Dec 19.

PMID:
23265571
[PubMed - indexed for MEDLINE]
4.

Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group.

McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan G el-H, Reda C, Yates AJ, Ravn P.

Ann Intern Med. 1998 Feb 15;128(4):253-61.

PMID:
9471927
[PubMed - indexed for MEDLINE]
5.

Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.

BJU Int. 2009 Dec;104(11):1637-40. doi: 10.1111/j.1464-410X.2009.08622.x. Epub 2009 Jun 22.

PMID:
19549260
[PubMed - indexed for MEDLINE]
6.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

Clin Ther. 2009 Apr;31(4):751-61. doi: 10.1016/j.clinthera.2009.04.018.

PMID:
19446148
[PubMed - indexed for MEDLINE]
7.

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.

J Urol. 2003 Jun;169(6):2008-12.

PMID:
12771706
[PubMed - indexed for MEDLINE]
8.

Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.

Israeli RS, Ryan CW, Jung LL.

J Urol. 2008 Feb;179(2):414-23. Review.

PMID:
18076933
[PubMed - indexed for MEDLINE]
9.

Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.

Tee SI, Yosipovitch G, Chan YC, Chua SH, Koh ET, Chan YH, Tan SS, Tsou IY, Tan SH.

Arch Dermatol. 2012 Mar;148(3):307-14. doi: 10.1001/archdermatol.2011.354. Epub 2011 Nov 21.

PMID:
22105813
[PubMed - indexed for MEDLINE]
10.

Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.

Kawahara T, Kobayashi T, Nishizawa K, Kobori G, Mitsumori K, Ogura K.

Hinyokika Kiyo. 2008 Apr;54(4):261-6.

PMID:
18516917
[PubMed - indexed for MEDLINE]
Free Article
11.

A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.

Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL.

J Urol. 2009 Mar;181(3):1104-13; discussion 1113. doi: 10.1016/j.juro.2008.11.026. Epub 2009 Jan 23.

PMID:
19167733
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.

Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.

J Bone Miner Res. 2010 Oct;25(10):2239-50. doi: 10.1002/jbmr.119.

PMID:
20499357
[PubMed - indexed for MEDLINE]
13.

Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.

Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ.

J Rheumatol. 2009 Aug;36(8):1705-14. doi: 10.3899/jrheum.081207. Epub 2009 Jun 1.

PMID:
19487264
[PubMed - indexed for MEDLINE]
14.

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.

Miller PD, Epstein S, Sedarati F, Reginster JY.

Curr Med Res Opin. 2008 Jan;24(1):207-13.

PMID:
18042311
[PubMed - indexed for MEDLINE]
15.

Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy.

Ripps BA, VanGilder K, Minhas B, Welford M, Mamish Z.

J Reprod Med. 2003 Oct;48(10):761-6.

PMID:
14619641
[PubMed - indexed for MEDLINE]
16.

Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.

Smith MR.

Drugs Aging. 2003;20(3):175-83. Review.

PMID:
12578398
[PubMed - indexed for MEDLINE]
17.

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M.

N Engl J Med. 1995 Nov 30;333(22):1437-43.

PMID:
7477143
[PubMed - indexed for MEDLINE]
Free Article
18.

The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.

Lanza F, Sahba B, Schwartz H, Winograd S, Torosis J, Quan H, Reyes R, Musliner T, Daifotis A, Leung A.

Am J Gastroenterol. 2002 Jan;97(1):58-64.

PMID:
11808969
[PubMed - indexed for MEDLINE]
19.

Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.

Choi HJ, Im JA, Kim SH.

Maturitas. 2008 Jun 20;60(2):170-6. doi: 10.1016/j.maturitas.2008.05.003. Epub 2008 Jun 24.

PMID:
18572334
[PubMed - indexed for MEDLINE]
20.

Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.

Spanjol J, Maricić A, Valencić M, Oguić R, Krpina K, Protić A, Ivancić A, Bobinac M, Fuckar D, Vojniković B.

Coll Antropol. 2008 Oct;32 Suppl 2:79-81.

PMID:
19138011
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk